Ticker League

EBITDA for Insmed (INSM)

Latest filings through · Reported

Metric

TTM

−$1.08B

YoY change

+43.1%

5Y CAGR

—

Peak year (2009)

$120.31M

EBITDA history chart for Insmed (INSM) from 1999 to 2025

Latest: −$1.17B

EBITDA growth chart for Insmed (INSM) from 1999 to 2025

Latest: +43.1%

EBITDA history table for Insmed (INSM) from 1999 to 2025

  • 2025−$1.17B+43.1%
  • 2024−$818.79M+24.0%
  • 2023−$660.18M+47.6%
  • 2022−$447.37M+16.6%
  • 2021−$383.65M+53.2%
  • 2020−$250.37M+15.3%
  • 2019−$217.07M-26.5%
  • 2018−$295.18M+60.3%
  • 2017−$184.09M+8.1%
  • 2016−$170.24M+47.7%
  • 2015−$115.28M+33.9%
  • 2014−$86.09M+58.8%
  • 2013−$54.20M+35.3%
  • 2012−$40.05M-32.5%
  • 2011−$59.31M+857.7%
  • 2010−$6.19M-105.1%
  • 2009$120.31M-1000.0%
  • 2008−$13.37M-33.3%
  • 2007−$20.03M-60.7%
  • 2006−$51.00M+250.9%
  • 2005−$14.54M-46.9%
  • 2004−$27.39M+161.1%
  • 2003−$10.49M-69.3%
  • 2002−$34.15M-11.6%
  • 2001−$38.64M+27.5%
  • 2000−$30.31M+276.9%
  • 1999−$8.04M—

EBITDA values are taken from Insmed's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA at Insmed (INSM)

According to Insmed's latest reported financial statements, the company's current EBITDA (TTM) is −$1.08B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

2025's annual EBITDA for Insmed (INSM) came in at −$1.17B – surged 43.1% year-over-year.

Between 2009 and 2025, Insmed EBITDA plunged 1073.7%, falling from $120.31M to −$1.17B.

Across the available history, EBITDA reached its high of $120.31M in 2009 and its low of −$1.17B in 2025.

Insmed EBITDA by Year

Insmed EBITDA 2025: −$1.17B

Insmed EBITDA in 2025 was −$1.17B, surged 43.1% from 2024. This figure represents the lowest annual value in the available history.

Insmed EBITDA 2024: −$818.79M

2024's EBITDA for Insmed came in at −$818.79M, grew 24.0% from 2023.

Insmed EBITDA 2023: −$660.18M

Insmed posted EBITDA of −$660.18M in 2023, surged 47.6% from 2022.

Insmed EBITDA 2022: −$447.37M

In 2022, Insmed reported EBITDA of −$447.37M, grew 16.6% from 2021.

Insmed EBITDA 2021: −$383.65M

Insmed EBITDA in 2021 was −$383.65M.

See more financial history for Insmed (INSM).

Sector peers by EBITDA

Healthcare peers of Insmed (INSM), ranked by their latest EBITDA

Frequently asked questions

Insmed (INSM) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation